Rtw Investments, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1493215) · Explore on the interactive board
Rtw Investments, LP disclosed 84 US equity positions worth $11.7bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is MDGL at 9.1% of the reported book, followed by ARGX, PTCT. The top ten holdings are 47.7% of the book, and the portfolio behaves like about 30 equal-weight positions. Versus the prior filing it opened 9 new positions, added to 24, reduced 8 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Rtw Investments, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 9 new, 24 added, 8 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 9.1% | $1.1bn | 1,993,687 | 0% | held |
| 2 | ARGX ARGENX SE | Healthcare | 5.6% | $658.2m | 709,446 | 0% | held |
| 3 | PTCT PTC THERAPEUTICS INC | Healthcare | 5.4% | $631.9m | 7,746,415 | 0% | held |
| 4 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 5.3% | $620.4m | 5,061,175 | 0% | held |
| 5 | CGON CG ONCOLOGY INC | Healthcare | 5.2% | $605.0m | 8,514,590 | 22% | added |
| 6 | INSM INSMED INC | Healthcare | 4.4% | $516.3m | 4,842,880 | 0% | held |
| 7 | TNGX TANGO THERAPEUTICS INC | Healthcare | 3.7% | $434.5m | 13,900,620 | 5% | added |
| 8 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 3.2% | $377.5m | 4,251,996 | 2% | added |
| 9 | CELC CELCUITY INC | Healthcare | 3.0% | $345.8m | 3,304,903 | 9% | added |
| 10 | ERAS ERASCA INC | Healthcare | 2.8% | $328.8m | 17,946,754 | 11% | added |
| 11 | RDNT RADNET INC | Healthcare | 2.6% | $298.9m | 4,846,958 | 13% | added |
| 12 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.6% | $298.7m | 3,139,030 | 53% | added |
| 13 | NTRA NATERA INC | Healthcare | 2.3% | $271.4m | 1,000,000 | -20% | reduced |
| 14 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.2% | $260.3m | 7,796,895 | 114% | added |
| 15 | IRTC IRHYTHM HOLDINGS INC | Healthcare | 2.2% | $259.6m | 2,182,631 | 31% | added |
| 16 | CYTK CYTOKINETICS INC | Healthcare | 2.1% | $243.8m | 2,862,003 | 5% | added |
| 17 | KAILERA THERAPEUTICS INC | 2.0% | $237.4m | 10,776,820 | – | new | |
| 18 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.9% | $227.9m | 2,655,695 | 0% | held |
| 19 | GH GUARDANT HEALTH INC | Healthcare | 1.9% | $222.2m | 1,481,033 | 0% | held |
| 20 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.8% | $213.7m | 1,267,925 | 19% | added |
| 21 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.8% | $211.3m | 3,357,059 | 0% | held |
| 22 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.6% | $184.0m | 5,623,525 | 0% | held |
| 23 | UNIQURE NV | 1.5% | $181.5m | 3,941,572 | 52% | added | |
| 24 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 1.5% | $180.8m | 7,144,524 | 0% | held |
| 25 | RGEN REPLIGEN CORP | Healthcare | 1.4% | $169.3m | 1,240,637 | 3% | added |
| 26 | URGN UROGEN PHARMA LTD | Healthcare | 1.4% | $167.2m | 4,543,895 | 0% | held |
| 27 | GHRS GH RESEARCH PLC | Healthcare | 1.4% | $159.5m | 5,933,815 | 0% | held |
| 28 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.3% | $154.6m | 4,869,798 | 0% | held |
| 29 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.3% | $151.4m | 10,700,974 | 1% | added |
| 30 | IMTX IMMATICS N.V | Healthcare | 1.1% | $131.1m | 12,946,176 | 1% | added |
| 31 | ZLAB ZAI LAB LTD | Healthcare | 1.1% | $124.9m | 6,574,032 | 0% | held |
| 32 | IMVT IMMUNOVANT INC | Healthcare | 1.0% | $122.4m | 3,177,849 | 0% | held |
| 33 | BLTE BELITE BIO INC | Healthcare | 0.9% | $110.2m | 715,332 | 0% | held |
| 34 | XNCR XENCOR INC | Healthcare | 0.9% | $109.1m | 6,777,461 | 0% | held |
| 35 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.8% | $92.3m | 13,560,258 | -1% | reduced |
| 36 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.8% | $89.4m | 2,309,021 | -58% | reduced |
| 37 | ALKS ALKERMES PLC | Healthcare | 0.7% | $87.6m | 1,672,356 | 0% | held |
| 38 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.7% | $86.3m | 1,607,507 | – | new |
| 39 | REPL REPLIMUNE GROUP INC | Healthcare | 0.7% | $82.0m | 7,411,581 | 1% | added |
| 40 | CSTL CASTLE BIOSCIENCES INC | Healthcare | 0.6% | $66.3m | 2,778,335 | 1% | added |
| 41 | CADL CANDEL THERAPEUTICS INC | 0.6% | $66.1m | 6,422,018 | 0% | held | |
| 42 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.5% | $60.5m | 17,687,772 | 0% | held |
| 43 | KOD KODIAK SCIENCES INC | Healthcare | 0.5% | $58.0m | 1,487,934 | 0% | held |
| 44 | AKTS AKTIS ONCOLOGY INC | 0.4% | $51.3m | 1,592,043 | 0% | held | |
| 45 | AXGN AXOGEN INC | Healthcare | 0.4% | $46.7m | 1,011,576 | – | new |
| 46 | DHR DANAHER CORP DEL | Healthcare | 0.4% | $43.8m | 230,000 | – | new |
| 47 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.4% | $43.1m | 2,364,347 | 39% | added |
| 48 | NGNE NEUROGENE INC | 0.4% | $42.8m | 1,362,456 | 0% | held | |
| 49 | HNGE HINGE HEALTH INC | Healthcare | 0.4% | $41.5m | 500,000 | -74% | reduced |
| 50 | OBIO ORCHESTRA BIOMED HLDGS INC | 0.4% | $41.2m | 9,556,063 | 15% | added |
What did Rtw Investments, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| APGE APOGEE THERAPEUTICS INC | 29.7% | $234.2m |
| APLSUSD APELLIS PHARMACEUTICALS INC | 18.8% | $148.2m |
| ISRG INTUITIVE SURGICAL INC | 12.9% | $101.4m |
| CNTA CENTESSA PHARMACEUTICALS PLC | 10.4% | $81.6m |
| CRNXGBP CRINETICS PHARMACEUTICALS IN | 6.7% | $52.7m |
| WAY WAYSTAR HLDG CORP | 5.0% | $39.3m |
| ARWR ARROWHEAD PHARMACEUTICALS IN | 4.7% | $36.7m |
| SYK STRYKER CORPORATION | 4.2% | $32.9m |
| CMPX COMPASS THERAPEUTICS INC | 2.8% | $22.1m |
| FLGT FULGENT GENETICS INC | 2.6% | $20.5m |
| JBIO JADE BIOSCIENCES INC | 1.0% | $8.1m |
| IVA INVENTIVA SA | 0.9% | $7.2m |
| OMDA OMADA HEALTH INC | 0.3% | $2.5m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 93.7% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Rtw Investments, LP's portfolio?
Across every quarter Rtw Investments, LP has filed, its median largest position is 9.8% of the book and its median top-ten weight is 48.9%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 13.0 completed holding spells, the median lasted 1.0 quarters; 84.0 positions are still open and their final length is unknown.